ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma.-MedSci.cn - 梅斯（MedSci）

ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma.

Mehdi, M; Thapa, B; Szabo, A; Ahmed, G; Shreenivas, AV; Thomas, JP; Sriram, D; Evans, DB; Tsai, S; Christians, KK; Erickson, B; Hall, WA; McFall, T; Patrick, S; George, B; Kurzrock, R; Kamgar, M

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (): 754

科室
- - 订阅+
  - 更多科室
工具
服务